longevitywatch

Qui est qui dans la recherche sur la longévité

Un panorama des chercheurs, instituts et entreprises qui comptent dans le domaine de la longévité.

43 chercheurs · 7 disciplines · 11 instituts · 17 entreprises

Une sélection choisie, non exhaustive, de noms reconnus, classés par discipline et volontairement pas par notoriété ni par influence.

Pour chacun, nous indiquons franchement sa position dans le domaine : salarié / fondateur veut dire salarié, fondateur ou actionnaire d’une entreprise du domaine, conseil / brevet signale des intérêts de conseil ou de brevet, et aucun intérêt connu veut dire que nous n’avons rien trouvé dans les sources publiques et les déclarations d’intérêts ; ce n’est pas une garantie. Pour la recherche elle-même, parcours nos thèmes et ce qui marche.

Aging clocks & biomarkers

Steve Horvathpatent inventor of epigenetic clocks; paid consultant to the Clock Foundation
Clock Foundation (until early 2026 Altos Labs)

Developed the first multi-tissue epigenetic aging clock in 2013, now the standard for measuring biological age.

Morgan Levineemployed at Altos Labs (departure announced for September 2026)
Altos Labs (San Diego)

Developed the PhenoAge clock, which predicts not just age but also disease risk.

Vadim Gladyshevadvisor to LongeVC, Thorne and Deep Longevity
Harvard Medical School

Pioneer in the reliability of methylation clocks and in quantifying biological age and rejuvenation.

Cellular reprogramming

Shinya Yamanakano known interest (unpaid advisor to Altos Labs)
Kyoto University (CiRA) and Gladstone/UCSF

2012 Nobel Prize for iPS cells: proved that adult cells can be reset to a young state, the foundation of the entire reprogramming field.

Wolf Reikemployed at Altos Labs
Altos Labs (Cambridge)

Discovered epigenetic reprogramming in development and demonstrated substantial rejuvenation of human cells through partial reprogramming.

Juan Carlos Izpisua Belmonteemployed at Altos Labs
Altos Labs (San Diego)

First to show that partial reprogramming can reverse hallmarks of aging in living mice.

Manuel Serranoemployed at Altos Labs; co-founder of Senolytic Therapeutics
Altos Labs (Cambridge)

Discovered the senescence gene p16 and connects senescence research to rejuvenation via reprogramming.

David Sinclairco-founder of multiple biotech companies (incl. Life Biosciences, MetroBiotech)
Harvard Medical School

Studies the epigenetic information-loss theory of aging, and is at once the most visible and most criticized public voice on lifespan.

Vittorio Sebastianoco-founder and head of research at Turn Biotechnologies
Stanford University

Developed transient rejuvenation (ERA) of adult cells without loss of their cell identity.

Senescence & senolytics

James Kirklandpatents on senolytics (via Mayo Clinic), licensed to companies
Cedars-Sinai (Center for Advanced Gerotherapeutics)

Co-founder of the senolytics field: coined the term and ran the first human studies on clearing senescent cells.

Tamara Tchkoniashareholder in Unity Biotechnology; patents on senolytics
Cedars-Sinai (Center for Advanced Gerotherapeutics)

Conceived the senolytics concept with Kirkland and developed the biomarkers and models of senescent cells.

Makoto Nakanishishareholder and advisor of reverSASP Therapeutics
University of Tokyo (IMSUT)

Uncovered the molecular control of cellular senescence, including senolysis via GLS1 inhibition.

Laura Niedernhoferco-founder of NRTK Biosciences; patents on senolytics
University of Minnesota (director, MIBAM)

Showed how endogenous DNA damage drives cellular senescence and aging, and brought the flavonoid fisetin into focus as a senolytic.

Genetics of exceptional longevity

Nir Barzilaiadvisor in the longevity sector (incl. investment fund LongeVC)
Albert Einstein College of Medicine (director, Institute for Aging Research)

Identified human longevity genes through centenarians and initiated the metformin trial TAME.

Cynthia Kenyonemployed at Calico (Alphabet)
Calico Life Sciences; emeritus, UCSF

Discovered that a single gene (daf-2) doubles the lifespan of worms, showing that aging is genetically controllable.

Eline Slagboomno known interest
Leiden UMC

Founder of the Leiden Longevity Study into the genetics and biomarkers of healthy aging in families.

Thomas Perlsno known interest
Boston University

Founder of the New England Centenarian Study, the largest centenarian study, and an outspoken critic of the anti-aging industry.

Sofiya Milmanno known interest
Albert Einstein College of Medicine

Showed in centenarians that reduced IGF-1 activity is associated with exceptional longevity.

Nutrition, metabolism & known drugs

Matt KaeberleinCEO of Optispan; co-founder of Ora Biomedical; several advisory boards
Optispan (Seattle)

Put rapamycin on the map as a candidate aging drug and is co-founder of the Dog Aging Project.

Richard Millerno known interest
University of Michigan

Leading figure of the ITP, the most rigorous program testing which compounds actually extend the lifespan of mice.

Valter Longofounder of L-Nutra (ProLon); equity and patents on the fasting-mimicking diet
USC (director, Longevity Institute)

Founder of the fasting-mimicking diet and of the research connecting nutrition to the pathways of aging.

Rafael de Cabono known interest
National Institute on Aging (NIA)

Leading research on caloric restriction and fasting patterns in mice and rhesus monkeys.

Dudley Lammingscientific advisory board of Aeovian Pharmaceuticals
University of Wisconsin-Madison

Unravels the mTOR pathway and showed that low-protein diets and restriction of BCAA amino acids improve metabolic health.

Eric Verdinco-founder of Napa, BHB and Selah Therapeutics; advisor incl. Amazentis
Buck Institute (President & CEO); UCSF

Studies how sirtuins, NAD+ and ketone bodies drive the aging process and inflammation.

Michael N. Hallprincipal investigator at Roche's Institute of Human Biology
Biozentrum, University of Basel

Discovered the TOR/mTOR protein, the switch controlling cell growth and aging and the target of rapamycin. 2024 Balzan Prize for the biological mechanisms of ageing.

Frank Madeoshareholder and advisor of TLL Longevity Labs (spermidineLIFE); equity in Samsara Therapeutics
University of Graz

Uncovered the role of spermidine in autophagy and cell protection, turning it into a fast-growing research field (spermidine as a fasting mimetic).

Johan Auwerxfounder and/or consultant of several companies incl. Amazentis/Timeline, Metro Biotech and Vandria
EPFL, Lausanne

Identified urolithin A as a mitophagy inducer and pioneered interventions targeting NAD+ and mitochondrial health.

Fundamental & comparative biology

Carlos López-Otínscientific advisor to Microviable Therapeutics
Universidad de Oviedo

Lead author of The Hallmarks of Aging, the influential framework that defines the core processes of aging.

Guido Kroemerco-founder of Samsara Therapeutics, Osasuna Therapeutics, everImmune and Therafast Bio
INSERM / Université Paris Cité (Cordeliers)

Discovered the role of mitochondrial membrane permeabilization in cell death and is a leader in autophagy research.

Linda Partridgeno known interest
UCL; founding director emeritus, Max Planck Cologne

Pioneered showing that diet and signaling pathways slow aging, consistently from fruit fly to mouse.

Steven Austadno known interest
University of Alabama at Birmingham

Pioneer of comparative aging biology, using long-lived species to study why organisms age so differently.

João Pedro de MagalhãesCSO of YouthBio Therapeutics; founder of consultancy Magellan Science
University of Birmingham

Built the widely used open databases on aging (AnAge, GenAge, DrugAge) that supply the field with data.

Vera Gorbunovaadvisory boards incl. Genflow Biosciences and DoNotAge
University of Rochester

Showed with the naked mole-rat that high-molecular-weight hyaluronan is the key to its cancer resistance and long life.

Andrei Seluanovno known interest
University of Rochester

Mapped the evolution of tumor suppression toward lifespan and, with Gorbunova, identified the hyaluronan mechanism.

Guang-Hui Liuno known interest
Chinese Academy of Sciences (Institute of Zoology), Beijing

Leads China's hub in aging biology: aging clocks, stem cells and the Aging Biomarker Consortium.

Björn Schumacherno known interest
University of Cologne / CECAD

Uncovered the central role of DNA damage in aging, including the discovery of the DREAM complex.

María Blascoco-founder of Telomere Therapeutics and Life Length
CNIO, Madrid (group leader, Telomeres & Telomerase)

One of the world's foremost telomere researchers, who demonstrated telomerase gene therapy in mice.

Coleen Murphyadvisory board of Zywie Bio (outside the longevity field)
Princeton University (director, Glenn Labs)

Mapped the networks behind long life and age-related memory loss using the roundworm C. elegans.

Adam Antebino known interest
Max Planck Institute for Biology of Ageing, Cologne (director)

Mapped the metabolic and hormonal control of lifespan, from worm to vertebrate (C. elegans and killifish).

K. Lenhard Rudolphno known interest
Leibniz Institute on Aging (FLI), Jena

Showed how telomere dysfunction drives stem-cell aging; former scientific director of the FLI.

Longevity medicine & prominent voices

Andrea Maierco-founder of longevity clinic Chi Longevity
National University of Singapore (director, Academy for Healthy Longevity)

Dutch physician-researcher bringing clinical longevity medicine into practice through large cohort studies and trials.

Brian KennedyCSO of Ponce de Leon Health (Rejuvant); board member at Gero; advisor to several biotechs
National University of Singapore (director, Centre for Healthy Longevity)

Uncovered the role of sirtuins and the mTOR pathway in aging; former CEO of the Buck Institute.

Aubrey de Greyleads the non-profit LEV Foundation; also advises commercial longevity companies
LEV Foundation (President & CSO)

Popularized the longevity escape velocity concept and the SENS approach, and is now testing combined rejuvenation in mice.

Instituts de référence

Novato, US

The world's first independent institute wholly dedicated to the biology of aging.

Bethesda, US

The US federal institute that leads and funds aging research.

Cologne, Germany

European hub for the molecular and evolutionary mechanisms of aging.

Los Angeles, US

The oldest and largest academic gerontology school in the world.

Beijing, China

Chinese hub for aging and regeneration research.

Singapore

Singapore's first center for clinical longevity medicine.

New York, US

Home of the Longevity Genes Project and the TAME trial.

Madrid, Spain

National cancer center that connects cancer and aging through telomere research.

Cologne, Germany

Leading German university cluster on cellular stress responses in aging-associated diseases.

Jena, Germany

Germany's first biomedical aging institute (2004); stem-cell aging and molecular damage.

Basel, Switzerland

Where the TOR/mTOR protein was discovered, the foundation of the rapamycin story.

Startups innovantes

D'où vient une bonne partie des travaux les plus récents (et les plus survendus). Objet et stade indiqués de façon neutre.

Altos LabsReprogramming
Redwood City, VS · Private

Heavily funded company using cellular reprogramming to rejuvenate cells (~$3 billion in initial capital).

South San Francisco, VS · Private (Alphabet)

Alphabet/Google subsidiary researching the fundamental biology of aging.

Retro BiosciencesReprogramming
SF Bay Area, VS · Private

Aims to extend healthy lifespan by ten years; funded by Sam Altman.

NewLimitReprogramming
South San Francisco, VS · Private

Resets aged cells to a younger gene-expression pattern; founded by Brian Armstrong.

Life BiosciencesReprogramming
Boston, VS · Private

Develops partial-reprogramming therapy; first human trial approved by the FDA (2026).

South San Francisco, VS · Publicly traded (Nasdaq: UBX)

Develops senolytic drugs that clear aged cells, with a focus on eye diseases.

Rejuvenate BioGene therapy
San Diego, VS · Private

Develops gene therapies against aging; spun out of George Church's lab.

BioAge LabsDrug development
Richmond, VS · Publicly traded (Nasdaq: BIOA)

Drug development based on human aging data; now focused on obesity and metabolic disease.

Hongkong / Boston · Publicly traded (HKEX)

Uses generative AI for drug discovery in aging and fibrosis.

LoyalCanine lifespan
San Francisco, VS · Private

Develops drugs that extend the healthy lifespan of dogs, with FDA recognition for senior dogs.

GeroAI/physics
Singapore · Private

Physics-first AI platform that models the dynamics of aging to find drugs.

Mountain View, VS · Private

Develops mRNA drugs (ERA platform) that reverse the epigenetic age of cells.

VandriaMitophagy
Nyon, Zwitserland · Private

Clinical-stage; oral small molecules that induce mitophagy to restore mitochondrial function (€116m raised).

Zürich, Zwitserland · Private

Swiss platform (formerly Rejuveron) building therapies against hallmarks of aging: senescence, telomeres and stem cells.

Londen, VK · Publicly traded (LSE)

Develops gene therapy based on a centenarian SIRT6 variant (GF-1002).

Lausanne, Zwitserland · Private

Spun out of EPFL; developed urolithin A (Mitopure) for mitochondrial health.

Graz, Oostenrijk · Private

Develops spermidine supplements (spermidineLIFE) based on the research of Frank Madeo.

Liens d'intérêts vérifiés en août 2026 à partir de sources publiques et de déclarations d'intérêts ; les affiliations et les intérêts peuvent changer. Tu vois une erreur ou un nom qui manque ? Dis-le-nous.

Newsletter

Reste au courant

Deux fois par semaine, les recherches sur la longévité qui comptent, dans ta boîte mail.